4615 related articles for article (PubMed ID: 6685926)
1. The stability of tissue plasminogen activator (t-PA).
Gaffney PJ; Templeman J; Curtis AD; Campbell PJ
Thromb Haemost; 1983 Oct; 50(3):650-1. PubMed ID: 6685926
[TBL] [Abstract][Full Text] [Related]
2. A collaborative study of a proposed international standard for tissue plasminogen activator (t-PA).
Gaffney PJ; Curtis AD
Thromb Haemost; 1985 Feb; 53(1):134-6. PubMed ID: 4039472
[TBL] [Abstract][Full Text] [Related]
3. A collaborative study to establish a standard for high molecular weight urinary-type plasminogen activator (HMW/u-PA).
Gaffney PJ; Heath AB
Thromb Haemost; 1990 Nov; 64(3):398-401. PubMed ID: 2128969
[TBL] [Abstract][Full Text] [Related]
4. A collaborative study to establish the 2nd international standard for tissue plasminogen activator (t-PA).
Gaffney PJ; Curtis AD
Thromb Haemost; 1987 Dec; 58(4):1085-7. PubMed ID: 3127919
[TBL] [Abstract][Full Text] [Related]
5. [Development of new thrombolytic substances].
Zeymer U; Neuhaus KL
Herz; 1994 Dec; 19(6):314-25. PubMed ID: 7843688
[TBL] [Abstract][Full Text] [Related]
6. Clinical experience with tissue plasminogen activator stored at -20 degrees C.
Grewing R; Mester U; Löw M
Ophthalmic Surg; 1992 Nov; 23(11):780-1. PubMed ID: 1484673
[TBL] [Abstract][Full Text] [Related]
7. Expression of plasminogen activators and plasminogen activator inhibitors in cutaneous melanomas of transgenic melanoma-susceptible mice.
de Vries TJ; Kitson JL; Silvers WK; Mintz B
Cancer Res; 1995 Oct; 55(20):4681-7. PubMed ID: 7553649
[TBL] [Abstract][Full Text] [Related]
8. The international standard for plasminogen activator inhibitor-1 (PAI-1) activity.
Gaffney PJ; Edgell TA
Thromb Haemost; 1996 Jul; 76(1):80-3. PubMed ID: 8819256
[TBL] [Abstract][Full Text] [Related]
9. In vitro clot lysis as a potential indicator of thrombus resistance to fibrinolysis--study in healthy subjects and correlation with blood fibrinolytic parameters.
Colucci M; Scopece S; Gelato AV; Dimonte D; Semeraro N
Thromb Haemost; 1997 Apr; 77(4):725-9. PubMed ID: 9134650
[TBL] [Abstract][Full Text] [Related]
10. [Anaphylactoid reaction during administration of tissue plasminogen activator (t-PA)].
Cannas S; De Leo A; Marzari A
G Ital Cardiol; 1997 Mar; 27(3):278-80. PubMed ID: 9244730
[TBL] [Abstract][Full Text] [Related]
11. Components of the plasminogen activation system in uveal melanoma--a clinico-pathological study.
De Vries TJ; Mooy CM; Van Balken MR; Luyten GP; Quax PH; Verspaget HW; Weidle UH; Ruiter DJ; Van Muijen GN
J Pathol; 1995 Jan; 175(1):59-67. PubMed ID: 7891228
[TBL] [Abstract][Full Text] [Related]
12. Effect of heat shock on the expression of urokinase-type plasminogen activator receptor in human umbilical vein endothelial cells.
Fukao H; Hagiya Y; Ueshima S; Okada K; Takaishi T; Izaki S; Matsuo O
Thromb Haemost; 1996 Feb; 75(2):352-8. PubMed ID: 8815589
[TBL] [Abstract][Full Text] [Related]
13. Fibrinolysis in patients with acute ischaemic heart disease. With particular reference to systemic effects of tissue-type plasminogen activator treatment on fibrinolysis, coagulation and complement pathways.
Munkvad S
Dan Med Bull; 1993 Sep; 40(4):383-408. PubMed ID: 8222763
[TBL] [Abstract][Full Text] [Related]
14. Plasminogen activator and plasminogen activator inhibitor gene expression in human saphenous vein organ culture.
Javed Q; Swanson N; Warner EL; Gershlick AH; de Bono DP
Exp Mol Pathol; 2001 Apr; 70(2):146-53. PubMed ID: 11263957
[TBL] [Abstract][Full Text] [Related]
15. Non neutralizing antibodies to tissue type plasminogen activator in the serum of acute myocardial infarction patients treated with the recombinant protein.
Cugno M; Cicardi M; Colucci M; Bisiani G; Merlini PA; Spinola A; Paonessa R; Agostoni A
Thromb Haemost; 1996 Aug; 76(2):234-8. PubMed ID: 8865537
[TBL] [Abstract][Full Text] [Related]
16. [t-PA in thrombolytic therapy of acute myocardial infarct].
Rutsch W; Schmutzler H
Herz; 1994 Dec; 19(6):336-52. PubMed ID: 7843690
[TBL] [Abstract][Full Text] [Related]
17. Synergistic induction of t-PA by vascular endothelial growth factor and basic fibroblast growth factor and localization of t-PA to Weibel-Palade bodies in bovine microvascular endothelial cells.
Pepper MS; Rosnoblet C; Di Sanza C; Kruithof EK
Thromb Haemost; 2001 Aug; 86(2):702-9. PubMed ID: 11522025
[TBL] [Abstract][Full Text] [Related]
18. Effects of liver blood flow on the pharmacokinetics of tissue-type plasminogen activator (alteplase) during thrombolysis in patients with acute myocardial infarction.
van Griensven JM; Koster RW; Burggraaf J; Huisman LG; Kluft C; Kroon R; Schoemaker RC; Cohen AF
Clin Pharmacol Ther; 1998 Jan; 63(1):39-47. PubMed ID: 9465840
[TBL] [Abstract][Full Text] [Related]
19. Urokinase (u-PA) is produced by collecting duct principal cells and is post-transcriptionally regulated by SV40 large-T, arginine vasopressin, and epidermal growth factor.
Piedagnel R; Tiger Y; Lelongt B; Ronco PM
J Cell Physiol; 2006 Feb; 206(2):394-401. PubMed ID: 16155905
[TBL] [Abstract][Full Text] [Related]
20. Properties of chimeric (tissue-type/urokinase-type) plasminogen activators obtained by fusion at the plasmin cleavage site.
Colucci M; Cavallo LG; Agnelli G; Mele A; Bürgi R; Heim J; Semeraro N
Thromb Haemost; 1993 May; 69(5):466-72. PubMed ID: 8391727
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
